What are the most common side effects of tirzepatide?

The most common side effects are gastrointestinal, including nausea, vomiting, and diarrhea. These are more frequent with tirzepatide than with insulin, particularly when starting the medication or increasing the dose. They often improve over time.

Is tirzepatide better than insulin for type 2 diabetes?

This review found tirzepatide superior to insulin for weight loss, blood sugar control, and safety in clinical trials. However, the best treatment depends on your individual health profile. Speak with your doctor about what is right for you.

What doses of tirzepatide were studied?

The review looked at three weekly injection doses: 5 mg, 10 mg, and 15 mg. All three doses showed significant benefits over insulin, and higher doses generally produced greater weight loss and blood sugar improvements.

Tirzepatide Review: Weight Loss & Blood Sugar Results

Key takeaways

✓Up to 14.5 kg more weight loss compared to insulin at the highest dose
✓Over 11 times more likely to reach normal blood sugar levels versus insulin
✓50–56% fewer low blood sugar episodes compared to insulin users
✓23–29% fewer serious adverse events than insulin across all doses
✓Higher doses produce progressively greater benefits for both weight and blood sugar

Quick specs

Journal	Expert opinion on drug safety
Year	2026
PMID	41200927

What This Study Found

Researchers analyzed 13 clinical trials involving over 14,000 people with type 2 diabetes and/or obesity to compare tirzepatide (brand name Mounjaro) against insulin, placebo, and other GLP-1 medications.

Key Results

Weight Loss: Tirzepatide caused significant weight loss compared to insulin, with results depending on the dose:

5 mg dose: lost an average of 10.2 kg (about 22 lbs) more than insulin users
10 mg dose: lost an average of 12.5 kg (about 27.5 lbs) more
15 mg dose: lost an average of 14.5 kg (about 32 lbs) more

Blood Sugar Control: People taking the 15 mg dose were over 11 times more likely to reach normal blood sugar levels compared to insulin users. HbA1c (a 3-month blood sugar average) dropped significantly across all doses.

Safety Highlights: Compared to insulin, tirzepatide users had:

23–29% fewer serious adverse events
50–56% fewer episodes of low blood sugar (hypoglycemia)
More gastrointestinal side effects (nausea, vomiting, diarrhea)

What This Means for Patients

Tirzepatide works by targeting two hormone receptors (GIP and GLP-1) that regulate blood sugar and appetite. This dual action appears to make it more effective than single-target medications. The higher the dose, the greater the benefits — though side effects also increase.

Important Considerations

While these results are promising, tirzepatide is not right for everyone. Gastrointestinal side effects are common, especially when starting treatment. Always discuss with your doctor whether this medication suits your individual health needs and circumstances.

References & Sources

Frequently asked questions

Tirzepatide (Mounjaro) targets two hormones — GIP and GLP-1 — that control blood sugar and appetite. Most other diabetes injections only target one hormone, which may explain why tirzepatide produces greater weight loss and blood sugar improvements.

Editorial note

This article is for educational purposes only and does not constitute medical advice. Always consult your healthcare provider before making changes to your diabetes management. Last reviewed: July 16, 2026 by the MDS Diabetes editorial team.

What to do next

📚

Tirzepatide Leads in Weight Loss & Blood Sugar Control